3830431G21Rik Inhibitors
The chemical class designated as Plekhd1 Inhibitors refers to a broad spectrum of molecular compounds that interact with and modulate cellular processes, potentially affecting the function of proteins like Plekhd1. Plekhd1, or pleckstrin homology domain-containing protein 1, is a protein that is thought to be involved in intracellular signaling and cytoskeletal organization, although its specific biological functions remain to be fully elucidated. Compounds that fall under the umbrella of Plekhd1 inhibitors typically do not target the Plekhd1 protein directly. Instead, they influence various regulatory mechanisms and molecular pathways that can indirectly impact the activity of Plekhd1. These inhibitors work at the molecular level, engaging with enzymes, structural proteins, and signaling pathways that orchestrate a range of cellular functions, some of which are presumed to be associated with the domain structures and activities of Plekhd1.
The way these compounds interact with cellular processes is varied, reflecting the complexity of the intracellular environment and the intricate nature of protein functions. For instance, some of these chemicals are known to inhibit enzymes like phosphoinositide 3-kinases (PI3K), which play a pivotal role in cell signaling and can affect the dynamics of the actin cytoskeleton, an area where Plekhd1 is speculated to have relevance. Other compounds might target microtubule stability, either stabilizing or depolymerizing these critical components of the cellular skeleton, thereby affecting the spatial organization of cells and the positioning of organelles, which can indirectly relate to Plekhd1's role given its domain composition. Still, other inhibitors may act on actin polymerization or myosin function, which are essential for maintaining the cellular architecture and for the process of vesicle trafficking - processes that Plekhd1 could potentially influence due to its pleckstrin homology domain.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which may indirectly affect PLEKHD1 function by altering PI3K signaling that can modulate actin cytoskeleton dynamics and membrane trafficking, processes where pleckstrin homology domain-containing proteins are often involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, which can alter cellular processes such as vesicular trafficking and cytoskeletal organization that are potentially regulated by PLEKHD1 through its pleckstrin homology domain. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
A microtubule-stabilizing agent that can disrupt microtubule dynamics. Given the potential coiled-coil domains of PLEKHD1, which can be involved in microtubule interactions, altering microtubule stability can indirectly influence PLEKHD1-associated cellular activities. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
A microtubule-depolymerizing agent that can affect microtubule dynamics and disrupt processes where PLEKHD1 may interact with microtubules through its coiled-coil domains. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
An inhibitor of actin polymerization, which can impact the actin cytoskeleton, potentially affecting PLEKHD1's role in membrane deformation or vesicle trafficking if PLEKHD1 is involved in those processes through its pleckstrin homology domain. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
An inhibitor of myosin light chain kinase (MLCK), which can affect actin-myosin contractility. Given the potential involvement of PLEKHD1 in cytoskeletal dynamics, ML-7 can indirectly influence PLEKHD1's cellular context by altering actin cytoskeleton tension and dynamics. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, which can affect actin organization and cell motility. If PLEKHD1 interacts with the actin cytoskeleton, modifying the Rho/ROCK pathway can indirectly affect its cellular functions. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $71.00 $260.00 $485.00 $949.00 | ||
An inhibitor of myosin II ATPase activity, which can alter cellular contractility and potentially impact processes influenced by PLEKHD1 if it is linked to actin-myosin dynamics. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which may indirectly influence PLEKHD1 by altering signaling pathways that affect cytoskeletal dynamics and membrane trafficking. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor, which can impact signaling pathways related to cell growth and cytoskeleton organization, potentially affecting PLEKHD1's cellular context. | ||||||